Objective
African-American (AA) men have excess mortality from prostate cancer (PCa) compared to White men, which has remained unchanged over several decades. The purpose of this study is to determine if race/ethnicity is an independent predictor of receipt of any definitive treatment vs watchful waiting/active surveillance (WW/AS).
Methods and Materials
Men diagnosed with PCa from 2004 to 2011 were identified from the Surveillance, Epidemiology and End-Results (SEER) program. Multinomial logistic regression analysis was performed to determine the relative risk ratio (RRR) of receipt of radical prostatectomy (RP), external beam radiation therapy (RT), brachytherapy, cryotherapy, or combination therapy vs WW/AS.
Results
Compared to White men, AA men were significantly less likely to receive RP (RRR 0.53, p<0.001), brachytherapy (RRR 0.72, p<0.001), cryotherapy (RRR 0.84, p=0.001), and combination therapy (RRR 0.70, p<0.001), and more likely to receive RT (RRR 1.03, p=0.041) versus AS/WW. Hispanic men were significantly less likely to receive RP (RRR 0.84, p<0.001) and brachytherapy (RRR 0.77, p<0.001), and more likely to receive RT (RRR 1.08, p<0.001) and cryotherapy (RRR 1.19, p=0.005) versus AS/WW compared to White men.
Conclusions
The disparate risk of receiving definitive treatment among AA and Hispanic men represents a significant public health issue that requires efforts to improve physician education, increase cultural competency, and ensure equitable access.